Literature DB >> 23565886

Neurodevelopmental outcome of extremely premature infants exposed to incomplete, no or complete antenatal steroids.

Sanjay Chawla1, Roopali Bapat, Athina Pappas, Rebecca Bara, Marwan Zidan, Girija Natarajan.   

Abstract

OBJECTIVE: To compare the neurodevelopmental outcomes at 18-22 months' corrected age of extremely premature infants exposed to a complete course, an incomplete course or no dose of antenatal steroids (ANS).
METHODS: Retrospective chart review of extremely premature (<28 weeks gestational age) neonates over a 3-year period. Neurodevelopmental assessment at 18-22 months' corrected age included a standardized neurologic examination and the Bayley Scales of Infant and Toddler development II or III. Intact survival was defined as survival without cerebral palsy (CP), blindness or deafness and mental developmental index (MDI)/cognitive score ≥85. Neurodevelopmental impairment (NDI) was defined as any of the following: moderate or severe CP, MDI/cognitive score <70, deafness or blindness. Patients were categorized into three groups: (A) no ANS; (B) incomplete course and (C) complete course of ANS.
RESULTS: Outcome data were available for 134 (88%) patients of our cohort (n = 153). Severe intraventricular hemorrhage (IVH) was significantly lower and intact survival was higher in the complete ANS group (p < 0.01). On logistic regression, with gestational age, gender, maternal insurance and ANS exposure as covariates, an incomplete (versus complete) course of ANS (p = 0.006) and gestational age were significantly associated with lower intact survival at 18-22 months.:
CONCLUSIONS: A complete course of ANS was associated with an increased likelihood of intact survival at a corrected age of 18-22 months among extremely premature infants, compared with an incomplete course. Follow-up studies should account for the differential benefit of complete versus incomplete course of ANS administration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23565886     DOI: 10.3109/14767058.2013.791273

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  6 in total

1.  Antenatal glucocorticoids and neonatal inflammation-associated proteins.

Authors:  Maheer Faden; Mari Holm; Elizabeth Allred; Raina Fichorova; Olaf Dammann; Alan Leviton
Journal:  Cytokine       Date:  2016-09-24       Impact factor: 3.861

2.  Association of Neurodevelopmental Outcomes and Neonatal Morbidities of Extremely Premature Infants With Differential Exposure to Antenatal Steroids.

Authors:  Sanjay Chawla; Girija Natarajan; Seetha Shankaran; Athina Pappas; Barbara J Stoll; Waldemar A Carlo; Shampa Saha; Abhik Das; Abbot R Laptook; Rosemary D Higgins
Journal:  JAMA Pediatr       Date:  2016-12-01       Impact factor: 16.193

3.  Increased Risk for Respiratory Complications in Male Extremely Preterm Infants: A Propensity Score Matching Study.

Authors:  Zhiwen Su; Lili Lin; Xi Fan; Chunhong Jia; Bijun Shi; Xiaoxia Huang; Jianwei Wei; Qiliang Cui; Fan Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

4.  Periviable birth: executive summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists.

Authors:  T N K Raju; B M Mercer; D J Burchfield; G F Joseph
Journal:  J Perinatol       Date:  2014-04-10       Impact factor: 2.521

5.  PPREMO: a prospective cohort study of preterm infant brain structure and function to predict neurodevelopmental outcome.

Authors:  Joanne M George; Roslyn N Boyd; Paul B Colditz; Stephen E Rose; Kerstin Pannek; Jurgen Fripp; Barbara E Lingwood; Melissa M Lai; Annice H T Kong; Robert S Ware; Alan Coulthard; Christine M Finn; Sasaka E Bandaranayake
Journal:  BMC Pediatr       Date:  2015-09-16       Impact factor: 2.125

Review 6.  Evidence for adverse effect of perinatal glucocorticoid use on the developing brain.

Authors:  Young Pyo Chang
Journal:  Korean J Pediatr       Date:  2014-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.